Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a shareholder update on March 13, 2026, authored by CEO Jim Joyce, detailing the company's strategic initiatives including a potential merger and asset sales. The update highlights the company's progress with its CardioDialysis platform, designed to treat cardiovascular disease and sepsis, while addressing the challenges of being an OTC-traded company.
Joyce, who previously founded Aethlon Medical and developed the Aethlon Hemopurifier, noted that Sigyn's CardioDialysis targets cholesterol-transporting lipoproteins and inflammatory molecules. Unlike lipoprotein apheresis devices limited to fewer than 60 specialized centers in the U.S., CardioDialysis is designed for use on dialysis machines at over 7,500 clinics nationwide. The technology also shows promise for traumatic brain injury and sepsis, a condition with no approved therapy. Joyce pointed to Spectral Medical's PMX device, valued at approximately $300 million, as a benchmark, noting that CardioDialysis has been validated to reduce sepsis-inducing bacterial toxins and inflammatory mediators.
The CEO explained that Sigyn became public through a merger with an OTC company but failed to execute an uplist to Nasdaq due to a regulatory catch-22 involving SEC and Nasdaq requirements. As a result, the company is exploring a potential merger with a Nasdaq-listed company at risk of not meeting the $5 million minimum market value of listed securities requirement, as well as selling certain assets. Joyce encouraged shareholders to review his January 15th shareholder update for more details on strategies to reduce dilution.
The update underscores the company's focus on advancing its therapeutic candidates while navigating financial constraints. Sigyn's pipeline also includes ImmunePrep for optimizing immunotherapeutic antibodies, ChemoPrep for enhanced chemotherapy delivery, and ChemoPure to reduce chemotherapy toxicity. As of March 11, 2026, the company had 2,330,042 shares outstanding.
